查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604501

肿瘤学人工智慧 (AI) 市场：未来预测（2024-2029）

Artificial Intelligence (AI) in Oncology Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

肿瘤人工智慧（AI）市场预计将以 35.43% 的复合年增长率成长，到 2029 年，市场规模将从 2024 年的 19.63 亿美元增至 89.44 亿美元。

在人工智慧 (AI) 的帮助下，肿瘤学领域正在取得令人难以置信的突破。人工智慧的多重好处正在推动人工智慧在癌症研究中的日益普及，从而推动肿瘤学市场的人工智慧。此外，癌症患者的盛行率增加，加上人口老化和癌症风险的增加，预计也将推动该市场的发展。此外，市场参与者的研究计划以及对人工智慧整合和产品发布的资助正在进一步推动人工智慧在肿瘤学领域的发展。

此外，人工智慧相关医疗设备的产品核可数量不断增加预计也将加速市场扩张。例如，美国FDA核准的DermaSensor 是截至 2024 年 1 月第一个检测皮肤癌的人工智慧医疗设备。

人工智慧在癌症治疗中的未来应用具有革命性的潜力，包括精准医疗、早期检测和单独设计的治疗方法。这可能会彻底改变癌症的诊断和治疗，因为人工智慧可以在查看复杂的资料集时发现微妙的模式并提供即时见解。这个新时代有望改善患者的治疗结果和医疗保健服务。

肿瘤学人工智慧 (AI) 市场驱动因素

  • 肿瘤学人工智慧的优势有助于市场成长

肿瘤学人工智慧的关键成长要素是将人工智慧纳入癌症研究中可以获得的许多好处。例如，人工智慧演算法可以扫描乳房 X 光检查、 电脑断层扫描和 MRI 影像，以寻找癌症的早期症状。在这一领域，演算法经常识别人类放射科医生可能错过或遗漏的模式和异常值，从而有可能实现早期诊断并改善预后。对于肿瘤学家来说，人工智慧可以深入研究从患者资料、病历到临床指南的所有内容，以帮助制定治疗计划。

基于患者体型、位置和个性等因素，基于人工智慧的演算法将能够推荐最佳治疗途径。如有必要，人工智慧模型可以进一步分析患者临床记录和治疗史的资料，以预测疾病发作、治疗反应和预后。

肿瘤学人工智慧 (AI) 市场的地理格局

  • 北美在预测期内将经历指数级增长

预计在预测期内，北美将占据肿瘤人工智慧市场的重要份额。肿瘤学人工智慧的推出正在降低癌症治疗的总体成本，而不影响治疗质量，预计将对北美市场产生积极影响。促成这一增长的因素包括癌症患者数量的增加、人口老化、医疗保健领域的强大影响力以及人工智慧的采用。例如，根据美国癌症协会的数据，癌症是美国第二大死因，2022 年约有 190 万例病例和 6,090,360 人因癌症死亡。根据同一消息来源，美国成长最快的年龄层是 85 岁及以上的成年人。此外，Azra AI、IBM 和英特尔公司等大公司预计将透过其技术进步推动肿瘤人工智慧市场。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业明智以及其他子区隔。
  • 竞争格局：了解世界主要企业采取的策略策略，并了解透过正确的策略渗透市场的潜力。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何塑造未来市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中发现新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业有用且具有成本效益。

它有什么用？

产业与市场考量、商机评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

分析范围

  • 历史资料与预测（2022-2029）
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 收益成长率与预测分析：按细分市场/地区（按国家）
  • 公司概况（策略、产品、财务资讯、主要趋势等）

目录

第一章简介

  • 市场概况
  • 市场定义
  • 分析范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章 分析方法

  • 分析设计
  • 分析过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章肿瘤学人工智慧 (AI) 市场：按组件类型

  • 介绍
  • 软体解决方案
  • 硬体
  • 服务

第六章肿瘤学人工智慧 (AI) 市场：按癌症类型分类

  • 介绍
  • 乳癌
  • 肺癌
  • 摄护腺癌
  • 大肠直肠癌
  • 脑肿瘤
  • 其他的

第七章肿瘤学人工智慧 (AI) 市场：按治疗类型

  • 介绍
  • 化疗
  • 放射治疗
  • 免疫疗法
  • 其他的

第八章肿瘤学人工智慧（AI）市场：按地区

  • 介绍
  • 北美洲
    • 依组件类型
    • 按癌症类型
    • 按治疗类型
    • 按国家/地区
  • 南美洲
    • 依组件类型
    • 按癌症类型
    • 按治疗类型
    • 按国家/地区
  • 欧洲
    • 按组件类型
    • 按癌症类型
    • 按治疗类型
    • 按国家/地区
  • 中东/非洲
    • 按组件类型
    • 按癌症类型
    • 按治疗类型
    • 按国家/地区
  • 亚太地区
    • 按组件类型
    • 按癌症类型
    • 按治疗类型
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 企业合併(M&A)、协议与合作
  • 竞争对手仪表板

第十章 公司简介

  • Azra AI
  • IBM
  • Siemens Healthcare GmbH
  • Intel Corporation
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • ConcertAI
  • Median Technologies
  • PathAI
简介目录
Product Code: KSI061615764

The Artificial Intelligence (AI) in oncology market is expected to grow at a CAGR of 35.43%, reaching a market size of US$8.944 billion in 2029 from US$1.963 billion in 2024.

The oncology discipline has seen tremendous breakthroughs with the help of artificial intelligence (AI). Multiple advantages of AI are driving its increased adoption in cancer studies, thereby propelling AI in the oncology market. Moreover, the growing prevalence of cancer cases coupled with an aging population and their higher risk of cancer is also expected to boost this market. Additionally, market players' research initiatives and funds for AI incorporation and product launches are further aiding AI in the oncology market.

Additionally, growing product approval of medical devices linked to AI is projected to accelerate market expansion. For instance, the U.S. FDA-approved DermaSensor is the first AI medical device to detect skin cancer as of January 2024.

Future applications of AI in cancer care would hold revolutionary promise and include precision medicine, early detection, and individually designed treatment regimens. This can completely change cancer diagnosis and treatment, as AI can spot minute patterns when viewing complex dataset moats and giving real-time insights. With such a new epoch, better patient outcomes and healthcare delivery would emerge.

Artificial intelligence (AI) in oncology market drivers

  • Advantages of AI in Oncology is contributing to its market growth

A major growth driver of AI in the oncology market is the many benefits of including AI in cancer studies. For instance, AI algorithms can scan mammograms, CT scans, or MRI images for early symptoms of cancer. This area is where algorithms frequently identify patterns and outliers that human radiologists may not see or even miss, thus leading to earlier diagnosis and possibly better outcomes. For oncologists, AI would peruse everything, from patient data and medical history to clinical guidelines, in support of the design of a treatment plan.

Based on factors such as the size, site, and character of patients, AI-based algorithms would be capable of recommending optimum pathways in treatment. AI models, if needed, can further analyze data from patient clinical records and treatment histories to predict the development of an illness, treatment response, and prognosis.

Artificial intelligence (AI) in oncology market geographical outlook

  • North America is witnessing exponential growth during the forecast period

The North American region is expected to hold a significant share of AI in the oncology market during the forecasted period. The launch of AI for oncology has reduced overall cancer treatment costs without affecting the quality of treatment, which is anticipated to positively impact the North American market. Various factors attributed to this growth are rising cancer cases, an aging population, a strong healthcare presence, and the adoption of AI. For example, cancer is the second-most leading cause of death in the US, as per the American Cancer Society, with around 1.9 million cases in 2022 and 6,09,360 cancer deaths in the country. As per the same source, the fastest-growing age group in the US is adults over 85. Moreover, major market players such as Azra AI, IBM, and Intel Corporation are further expected to propel AI in the oncology market through technological advancements.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2029
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The artificial intelligence (AI) in oncology market is segmented and analyzed as follows:

By Component Type

  • Software Solutions
  • Hardware
  • Services

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others

By Treatment Type

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY COMPONENT TYPE

  • 5.1. Introduction
  • 5.2. Software Solutions
  • 5.3. Hardware
  • 5.4. Services

6. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY CANCER TYPE

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Lung Cancer
  • 6.4. Prostate Cancer
  • 6.5. Colorectal Cancer
  • 6.6. Brain Tumor
  • 6.7. Others

7. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY TREATMENT TYPE

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Radiotherapy
  • 7.4. Immunotherapy
  • 7.5. Others

8. ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Component Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By Treatment Type
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Component Type
    • 8.3.2. By Cancer Type
    • 8.3.3. By Treatment Type
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Component Type
    • 8.4.2. By Cancer Type
    • 8.4.3. By Treatment Type
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Component Type
    • 8.5.2. By Cancer Type
    • 8.5.3. By Treatment Type
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Component Type
    • 8.6.2. By Cancer Type
    • 8.6.3. By Treatment Type
    • 8.6.4. By Country
      • 8.6.4.1. Japan
      • 8.6.4.2. China
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Azra AI
  • 10.2. IBM
  • 10.3. Siemens Healthcare GmbH
  • 10.4. Intel Corporation
  • 10.5. GE HealthCare
  • 10.6. NVIDIA Corporation
  • 10.7. Digital Diagnostics Inc.
  • 10.8. ConcertAI
  • 10.9. Median Technologies
  • 10.10. PathAI